← Back to patent-cliff list
SRSD-216
Tier C — Watch / tradeSRSD-216
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：Lp(a)
Indications (approved)：高脂蛋白血症, Cardiac and vascular disorders
Regional status
US
Phase II
2025-03-25
EU
-
China
Phase II
2025-04-07
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SRSD-216?
Approved indications include: 高脂蛋白血症, Cardiac and vascular disorders.
When does the SRSD-216 patent expire?
No public expiry year is available for SRSD-216 yet; this page updates once verified.
How do I get a quote for SRSD-216 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30